Key Takeaways REGN will report Q2 results on Aug. 1, with EPS and revenue estimates at $8.15 and$3.31B, respectively.Higher Dupixent profits and strong Eylea HD uptake may offset legacy Eylea sales pressure.New approvals for Dupixent and Lynozyfic expand Regeneron's pipeline. Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. ((REGN) reports second-quarter 2025 results on Aug. 1, 2025.The Zacks Consensus Estimate for revenues i ...